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Abstract
Background and Aims Intestinal stem cell organoid transplantation generates functional intestinal neomucosa and has been
used therapeutically to improve nutrient absorption and cure bile acid malabsorption in rats. We hypothesized that intestinal
organoids can be harvested and transplanted to generate intestinal neomucosa in a large animal model.
Materials and Methods In group 1, 2-month old beagles (n=6) underwent autotransplantation of intestinal organoids
prepared from a segment of their own ileum. In group 2, intestinal organoids were harvested from fetuses and
allotransplanted into 10-month old mother animals (n=4). Tissues were harvested after 4 weeks and analyzed by
hematoxylin and eosin histology and fluorescent microscopy.
Results Large numbers of viable organoids were harvested in both groups. In group 1, no neomucosal growth was identified
in any of the engraftment sites after autotransplantation of juvenile organoids. In group 2, neomucosal growth with large
areas of crypts and villi was identified in 11 of 12 polyglycolic acid scaffolds after allotransplantation of fetal organoids.
The neomucosa resembled normal canine mucosa in structure and composition.
Conclusions Intestinal stem cell organoid transplantation can be used to generate neomucosa in dogs. This is the first report
of successful generation of intestinal neomucosa using intestinal stem cell organoid transplantation in a large animal model.
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DMEM Dulbecco’s modified Eagle medium
DTT dithiothreitol
EDTA ethylenediamine tetra-acetic acid
H&E hematoxylin and eosin
HBSS* Hanks’ buffered saline solution
NAC N-acetyl cysteine





Massive loss of small bowel leads to a short bowel
syndrome with significant morbidity, including malnutri-
tion, diarrhea, electrolyte abnormalities, profound dehydra-
tion, and failure to thrive.1–3 Current therapeutic options for
short bowel syndrome are limited. They include total par-
enteral nutrition, bowel lengthening procedures, and small
bowel transplantation, all of which carry significant mor-
bidity and mortality.4 Many patients with these conditions
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could be more effectively treated if healthy mucosa were
available in larger quantities as a replacement or functional
supplement. Hence, methods to generate neomucosa, for
example, by transplanting intestinal mucosal stem cells,
represent a potentially appealing alternative.
Intestinal stem cell “organoids” are multi-cellular aggre-
gates of intestinal mucosal progenitors and putative
mucosal stem cells, which surround a core of mesenchymal
stromal cells.5 Organoids are the smallest transplantable
unit of this mucosal tissue identified to date. Transplanta-
tion of intestinal organoids has been shown to generate
intestinal neomucosa in rats that resembles native intestine
in both structure and function.6–11 We have recently shown
that transplantation of rat ileal organoids into debrided
segments of jejunum generates a “neo-ileum” that com-
pletely reverses bile acid malabsorption in rats that have
undergone ileal resection.10 In other studies, Grikscheit et
al. anastomosed tissue-engineered mucosal cysts to the
native intestine at the time of an 85% enterectomy in rats
and showed that it reduced postoperative weight loss
compared with animals that underwent only small bowel
resection.11 Based on these studies, it is clear that intestinal
organoid transplantation has potential therapeutic benefits.
In spite of these successful rodent studies, successful
generation of neomucosa using intestinal organoid trans-
plantation has never been reported in large animals. In the
present study, we show that the isolation and transplanta-
tion of intestinal organoids can be used to generate
neomucosa in a dog model.
Materials and Methods
Animals
Beagles were obtained from Marshall Farms (North Rose,
NY, USA). Animals were allowed an acclimatization period
of 1 week before participation in experiments in accordance
with Institutional Animal Care and Use Committee guide-
lines. All animals were housed in accordance with the Nation-
al Institutes of Health guidelines for the care of laboratory
animals, maintained under a 12-hour light/dark cycle (6 A.M.
to 6 P.M.) and received standard dog chow twice a day
(Nestle Purina, St. Louis, MS, USA) and water ad libitum.
Study Design
Preliminary pilot experiments were performed on three
2-month-old beagles (P1, P2, and P3) to optimize the method
of intestinal organoid isolation (Table 1). We aimed to obtain
clusters that were microscopically similar to those produced
with our previously successful rodent protocols.8,10,12,13
We then conducted two different types of experiments
involving autotransplantation of organoids and allotrans-
Table 1 Study Overview






Implantation location Bioscaffold Implantation
results
Pilot P1 Adult ileum No No n/a n/a n/a
P2 Adult ileum No No n/a n/a n/a
P3 Adult ileum No No n/a n/a n/a
Autotransplantation Auto-1 Adult ileum No Yes Subcutaneous Tissue None No mucosa
Auto-2 Adult ileum No Yes Omentum PGA No mucosa
Auto-3 Adult ileum CFDA Yes Surgically debrided intestine None No mucosa
Unlabeled control Yes Surgically debrided intestine None No mucosa
CFDA Yes Chemically debrided intestine None No mucosa
Unlabeled control Yes Chemically debrided intestine None No mucosa
Auto-4 Adult ileum CFDA/Dil Yes Surgically debrided intestine None No mucosa
Unlabeled control Yes Surgically debrided intestine None No mucosa
CFDA/Dil Yes Omentum None No mucosa
Unlabeled control Yes Omentum None No mucosa
Auto-5 Adult ileum DsRed lentivirus Yes Surgically debrided intestine None No mucosa
Unlabeled control Yes Surgically debrided intestine None No mucosa
Auto-6 Adult ileum DsRed lentivirus Yes Omentum PGA No mucosa
unlabeled control Yes Omentum PGA No mucosa
Allotransplantation Allo-1 Fetal intestine No Yes Omentum PGA Mucosa
Allo-2 Fetal intestine No Yes Omentum PGA Mucosa
Allo-3 Fetal intestine No Yes Omentum PGA Mucosa
Allo-4 Fetal intestine No Yes Omentum PGA No mucosa
Experimental details for each subject in the pilot, autotransplantation, and allotransplantation groups are shown
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plantation of organoids, respectively. In experimental group
1,autotransplantation experiments were performed (Table 1).
Two-month-old male beagles were used as both donors for
intestinal stem cell isolation and as recipients for transplan-
tation. The group consisted of six animals (n=6), Auto-1, 2,
3, 4, 5, and 6. In experimental group 2, allotransplantation
experiments were performed. Ten-month-old pregnant fe-
male beagles were used. The group consisted of four mother
animals (n=4), Allo-1, 2, 3, and 4. Their fetal pups
(gestational days 40–50) were removed via cesarean section
and used as the donors for the intestinal organoid isolation.
The mother animals were used as non-syngeneic recipients
of the intestinal organoids. All four animals had organoids
seeded onto tubularized polyglycolic acid (PGA) biopoly-
mers (Synthecon, Houston, TX, USA), which were wrapped
in omentum (Table 1).
Surgery
Animals were fasted 24 h before surgery and kept nothing
per os from the night before surgery. All pharmaceutical
drugs were obtained from McKesson Pharmaceutical (San
Francisco, CA, USA) unless otherwise noted. On the
morning of the surgery, each animal was sedated with
subcutaneously administered acepromazine (0.025 mg/kg;
Butler Animal Health Supply, Dublin, OH, USA) 1 h
before anesthesia. A transdermal fentanyl patch (25 μg/
72 h) was placed on the dorsal skin for perioperative pain
control. After intravenous administration of atropine
(0.05 mg/kg; Butler Animal Health Supply, Dublin, OH,
USA) and diazepam (0.275 mg/kg), the animal was
endotracheally intubated and maintained on inhaled iso-
flurane (0.8–2.0% in oxygen; Butler Animal Health Supply,
Dublin, OH, USA) anesthesia for the duration of the
procedure. Cefazolin (20 mg/kg) was administered intrave-
nously before making the skin incision. All suture materials
were obtained from Ethicon (Sommerville, NJ, USA).
Group 1—Autotransplantation
To harvest ileal organoids, a midline laparotomy was made
under sterile conditions. The distal 40 cm of ileum was
resected and transferred to the laboratory for ileal organoid
isolation. The proximal and distal resection sites were re-
anastomosed to restore the continuity of the gastrointestinal
tract. The animals were maintained under anesthesia while
the organoid isolation was performed.
Isolation of Juvenile Organoids
Intestinal organoids were isolated using a modification of a
technique described by Avansino et al.8 In brief, the 40-cm
length of excised ileum was rinsed with 1 l of pre-warmed
sterile 0.9% saline, followed by 4 l of pre-warmed
polyethylene glycol (PEG) (5.9% in water) (Braintree
Laboratories, Braintree, MA, USA) solution to remove the
large amounts of mucus present in the juvenile canine
intestine. The rinsed ileum was then opened longitudinally,
and the mucosa was scraped off with a glass slide and
minced into pieces. The tissue was transferred to a large
tissue culture flask and washed three times in calcium- and
magnesium-free Hanks’ buffered saline solution (HBSS*;
Mediatech Inc., Herndon, VA, USA), with 100 IU/ml
penicillin+100 μg/ml streptomycin (Gibco, Gaitersburg,
MD, USA) and 4 mM L-glutamine (Invitrogen, Carlsbad,
CA, USA). A fourth wash included 2 mM N-acetyl cysteine
(NAC; Abbott Laboratories, Chicago, IL, USA) as a
mucolytic agent. The epithelial clumps were shaken gently
for 10 min at room temperature. A final wash was
performed in HBSS*. The tissue was minced into ≤1 mm
pieces and transferred into an HBSS* solution containing
0.1 mg/ml dispase type 1 (Roche, Indianapolis, IN, USA)
and 300 U/ml collagenase type XI (Sigma, St Louis, MO,
USA) and shaken on the orbital incubator at 250 rpm at
37°C for 40 min. The suspension was transferred into
HBSS* with 2 mM NAC and shaken at room temperature
for 5 min. The contents were allowed to sediment for
1 min, and the upper mucous layer was removed and
discarded. The supernatant was transferred into HBSS* and
gently inverted and allowed to sediment for 2 min. The
upper mucus layer was removed and discarded and the step
repeated. Two parts of this cleared supernatant were mixed
with one part of Dulbecco’s modified Eagle’s medium
(Gibco, Gaitersburg, MD, USA) to which 2% D-sorbitol
(Sigma, St Louis, MO, USA), 2.5% fetal bovine serum
(FBS; Hyclone, Logan, UT, USA), and 100 IU/ml
penicillin+100 μg/ml streptomycin (Gibco, Gaitersburg,
MD, USA) had been added (DMEM-S). The mixture was
centrifuged at 1,600 rpm for 4 min at room temperature,
and the supernatant was decanted. The pellet was washed in
DMEM-S six times. The intestinal organoids were then
seeded directly or first labeled (see below) and then seeded.
Labeling of Intestinal Stem Cell Clusters with Fluorescent
Cell Markers
Carboxyfluorescein diacetate succinimidyl ester (Vybrant ®
CFDA SE) and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocar-
bocyanine perchlorate (Vybrant ® DiI) cell labeling solutions
were obtained from Invitrogen (Carlsbad, CA, USA). The
intestinal organoids were suspended at a density of 20,000
clusters per milliliter in DMEM-S and labeled for 10 min at
37°C following the manufacturer’s recommendations. The
suspensions were centrifuged at 1,500 rpm for 5 min at 37°C
and the supernatant discarded. The organoids were gently
resuspended in 37°C DMEM-S and washed three times. The
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organoids were then resuspended in DMEM-S and seeded. An
aliquot of organoids were left unlabeled to control for any
possible adverse effect that the labeling process may have had
on organoid viability. Organoid cell viability was tested with
Trypan blue (Invitrogen, Carlsbad, CA, USA) exclusion.
Lentiviral Transduction of Organoids with DsRed
Intestinal organoids (20,000 clusters ~2×106 cells) were
suspended in 600 μl of pre-warmed 37°C DMEM supple-
mented with 10% FBS, 100 IU/ml penicillin+100 μg/ml
streptomycin (Gibco, Gaitersburg, MD, USA), and diethy-
laminoethyl-dextran (DEAE-dextran; 16.7 μg/ml; Amer-
sham Biosciences, Piscataway, NJ, USA). The DsRed
lentiviral transfer vector RRLsin.cPPT.hPGK.DsRed.Wpre
(a kind gift from Dr. Hans-Peter Kiem, University of
Washington) expresses the fluorescent protein DsRed from
the internal human phosphoglycerate kinase promoter
containing a woodchuck hepatitis pre-element as well as a
central polyurine tract.14 Freshly thawed and pre-warmed
lentivirus in DMEM was added to the warm intestinal stem
cell solution and gently inverted. The final solution volume
had a final concentration of 1.08×106 IU of lentivirus per
milliliter and 10 μg/ml of DEAE-dextran. The mixture was
incubated at 37°C for 30 min with gentle inversion. The
cells were then washed six times in DMEM (with 10% FBS
and 100 IU/ml penicillin and 100 μg/ml streptomycin) to
remove any remaining virus. The pellet was resuspended in
DMEM and used for seeding. An aliquot of the transduced
organoids were transferred into tissue culture for 48 h to
confirm transduction efficiency.
Biopolymer Preparation and Sterilization
Non-woven sheets of PGA (2-mm thick, 95% void volume,
60 mg of PGA/ml, fiber diameter of 13 μm) were obtained
from Synthecon (Houston, TX, USA). The PGA polymer
sheets were tubularized into 1-cm long tubes with an
internal radius of 8 mm using 6-0 Vicryl suture. The tubes
were sterilized for 30 min in 80% ethanol and subsequently
rinsed with 1.5 l of sterile phosphate buffered solution
(PBS) (Fisher, Pittsburgh, PA). The tubes were placed into
a 0.3% collagen type 1 solution in PBS (Vitrogen 100,
Cohesion Tech, Palo Alto, CA, USA) for 30 min and then
rinsed with PBS. They were finally vacuum-dried (Speed
Vac, Savant Instruments, Farmingdale, NY, USA) for
30 min at 25°C and stored at 4°C under sterile conditions
in a vacuum desiccator until use.
Intestinal Organoid Seeding
Animals underwent seeding of the intestinal organoids into
(a) subcutaneous tissue (n=44), (b) omentum (n=6), (c)
biopolymer scaffolds wrapped in omentum (n=15), (d)
segments of mid-jejunum whose surface mucosa had been
chemically debrided with perfusion of the chelating agent
ethylenediamine tetra-acetic acid (EDTA; n=4), and (e)
segments of mid-jejunum whose mucosa had been surgi-
cally debrided with a no. 2 surgical curette (n=10). The
intestinal organoids were quantified, resuspended in
DMEM-S, and seeded with a pipette at a density of
20,000 organoids per square centimeter in all graft beds
(Fig. 1).
Implantation of Organoids into Subcutaneous Tissue In
dog Auto-1, 44 separate 5-mm incisions were made along
four rows on the back of the animal, and 20,000 organoids
in 500 μl HBSS* were seeded into each subcutaneous
pocket with and without matrigel.15 The skin was closed
with a 4-0 monocryl suture. The organoids were left in the
subcutaneous pockets for 4 weeks. For 22 of the organoid
implantations, 5 μl of India ink (Fisher Scientific, Fair
Lawn, NJ, USA) were mixed with the organoid suspension
to aid in the identification of the implantation site during
microscopic examination.
Implantation of Organoids into Omentum In dog Auto-4,
both labeled (n=3 sites) and unlabeled (n=3 sites) organo-
ids were seeded into the omentum. The omentum was
wrapped and secured around the organoids with 6-0
polypropylene suture.
Implantation of Organoids into Biopolymer Scaffolds In
dog Auto-2, non-labeled organoids were seeded onto the
inner lumen of three PGA tubes. In dog Auto-6, the inner
lumen of PGA tubes were seeded with either DsRed
Figure 1 Experimental design. The isolation and implantation of
organoids in the autotransplantation and allotransplantation groups.
Numbers in parentheses represent total number of implantations in
respective graft bed.
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lentiviral vector transduced organoids (n=6 tubes) or
unlabeled organoids (n=6 tubes). The seeded PGA tubes
were placed on ice for 30 min to allow attachment of the
organoids. The tubes were wrapped and secured in
omentum with 6-0 silk suture, marked with 6-0 polypro-
pylene sutures, and placed in the abdomen for 4 weeks
(Table 1).
Chemical Debridement of Jejunal Mucosa In dog Auto-3, a
20-cm segment of jejunum 80 cm proximal to the ileocecal
valve was isolated with its mesenteric blood supply intact
and the continuity of the gastrointestinal tract restored by
re-anastomosis. Both ends of the jejunal segment were
cannulated. The mucosal epithelium from the isolated
jejunum was chemically stripped using a modification of
the technique described by us previously.8 In brief, the
mesenteric blood vessels were cross-clamped, and the
jejunal segment was flushed vigorously with 1 l of 0.9%
saline, 4 l of 5.9% PEG solution, 0.9% saline containing
1 mM dithiothreitol (DTT) for 5 min, then 1 mM DTT/
27 mM citrate for 15 min and 1 mM DTT/3 mM EDTA for
60 min at a flow rate of 80 cc/min at 39°C. The debrided
segment was flushed with 3 l of HBSS* (Mediatech Inc.,
Herndon, VA, USA) and then seeded with ileal organoids.
The proximal and distal ends of the segment were sutured
closed with 4-0 polypropylene suture. The segment was
placed in the abdomen for 4 weeks.
Surgical Debridement of Jejunal Mucosa (Surgical
Mucosectomy) In dogs Auto-3, 4, and 5 (Table 1), a 20-cm
segment of jejunum 80 cm proximal to the ileocecal valve
was isolated with its mesenteric blood supply intact and the
continuity of the gastrointestinal tract restored by re-
anastomosis. The jejunum was opened along its antimesen-
teric border. Using a no. 2 surgical curette, the mucosa was
then scraped off. Bleeding from the graft bed was
controlled by compression with gauze soaked in epineph-
rine solution (10 μg/ml). Then, the intestinal organoids
were seeded onto the surface of the denuded intestine, the
intestine was sewn closed along its antimesenteric border
and its ends with a running 4-0 polypropylene suture, and
the segment was placed in the abdomen for 4 weeks.
Once the intestinal organoids were seeded in the
respective graft beds, the abdomen was closed in three
layers.
Histology
The animals were killed 4 weeks after organoid seeding
with pentobarbital overdose (100 mg/kg; Butler Animal
Health Supply, Dublin, OH, USA). The seeded subcutane-
ous tissue, omental tissue, biopolymer implants, and
intestinal tissue were harvested and cut transversely into
5-mm sections. Half of the tissue was mounted in OCT
compound (Ted Pella Inc., Redding, CA, USA) and used
for frozen sections. The other half of the tissue was fixed in
4% phosphate-buffered formalin for 24 h and paraffin-
embedded. Frozen sections were cut (5-µm thickness) on a
cryostat (Leica, Wetzlar, Germany) and mounted on glass
slides. The tissue was mounted with Vectashield hard
mount with 4′,6-diamidino-2-phenylindole (DAPI; Vector
Laboratories, Inc., Burlingame, CA, USA) to stain the
nuclei. Every tenth slide was evaluated for a fluorescent
signal (DsRed, CFDA, or DiI) that would indicate
engraftment of seeded cells. Immediately adjacent sections
were stained with hematoxylin and eosin (H&E) and
evaluated for presence of neomucosa. Likewise, paraffin-
embedded tissue was mounted on glass slides, stained with
H&E and evaluated for the presence of neomucosal growth.
Group 2—Allotransplantation
To harvest organoids, fetuses were obtained from an
anesthetized pregnant female. A midline laparotomy and a
hysterotomy were made under sterile conditions. Each fetus
was removed, and its small intestine was harvested and
transferred to the laboratory for organoid isolation. Then,
the uterus of the mother was removed. The mother animal
remained under anesthesia until the stem cell preparation
was complete.
Isolation of Fetal Organoids
The intestinal organoids were isolated as described above
for experimental group 1 with the following exceptions.
PEG and NAC were not utilized, as the fetal intestine did
not contain significant mucus. Enzymatic digestion with
dispase and collagenase was performed for 25 min at 22°C.
Biopolymer Preparation and Sterilization
The PGA biopolymer tubes were prepared and sterilized as
described above for experimental group 1. Due to the
availability of biopolymers at the time of the individual
experiments, dog Allo-1 had five biopolymer tubes
implanted, dogs Allo-2 and Allo-3 each had three biopoly-
mer tubes implanted, and dog Allo-4 had only one
biopolymer tube implanted.
Intestinal Organoid Seeding
The intestinal organoids were seeded on the luminal surface
of the PGA at a density of 20,000 organoids per square
centimeter and implanted into omentum as described for
group 1. An unseeded PGA tube was implanted as a
negative control. The abdomen was closed in three layers.
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The biopolymer implants were left in the abdomen for
4 weeks before retrieval.
Immunosuppression
Transplant recipients underwent induction and maintenance
immunosuppression to prevent rejection of the intestinal
organoids. Each animal received 250 mg of IV solumedrol
intraoperatively before implantation of the fetal intestinal
organoids. Starting on postoperative day 1, the animals
were maintained on oral cyclosporine dosed at 100 mg
twice daily (Novartis, New York, NY, USA). Animals
received 500 mg methylprednisolone as an intravenous
infusion immediately before cell implantation intraopera-
tively. Postoperative oral prednisone was tapered as follows:
20 mg per os daily×4 days, 10 mg per os daily×4 days, then
maintenance dose of 5 mg per os daily until the end of the
experiment. Systemic cyclosporine levels were checked on
postoperative days 5 and 14.
Histology
The animals were killed at 4 weeks after seeding as
described for group 1. All tissues were fixed in 4%
phosphate-buffered formalin for 24 h and paraffin-
embedded and analyzed for presence of neomucosa as
described. The total amount of neomucosa per biopoly-
mer tube was calculated by determining the percentage of




All animals survived to the end of the experimental period
without complications.
Isolation of Organoids
In the dogs of the pilot group, the ileum used to isolate the
ileal organoids contained and released large amounts of
mucus during the preparation. This mucus hindered
effective enzymatic digestion and release of organoids. A
modified isolation protocol using PEG and NAC was
devised, which effectively removed the mucus. The
harvested organoids microscopically resembled the neona-
tal rat organoids that we have harvested in previous
experiments.8,10,12 The modified harvest protocol was used
for all dogs in the autotransplantation group. An average of
1,430,000±530,000 organoids per ileum was obtained.
Fetal intestine used in the allotransplantation experiments
did not require the use of PEG and NAC in the digestion
protocol, as the fetal intestine did not contain any appre-
ciable mucus. The digestion yielded on average 213,000±
22,000 organoids per isolation. The organoids obtained
from fetal intestine were microscopically indistinguishable
from the organoids obtained from the juvenile ileum.
Furthermore, when the number of organoids harvested
was controlled for by weight of donor tissue, the
organoid yield per gram tissue was similar between the
autotransplantation and allotransplantation groups. Orga-
noid preparations took 180 to 200 min in all cases, and
there was no difference between groups. The recipients
were kept under anesthesia while organoid suspensions
were prepared.
Labeling of Intestinal Stem Cell Clusters with Fluorescent
Markers
In dog Auto-3, an aliquot of organoids were labeled with
CFDA before implantation. In dog Auto-4, aliquots of
organoids were labeled with either CFDA or DiI before
implantation. All organoids labeled with fluorescent vital
stains were readily seen under fluorescent microscopy
before implantation. Uniform staining of the organoid
clusters was achieved with CFDA and DiI (Figs. 2a, b).
Lentiviral Transduction of Organoids with DsRed
In dogs Auto-5 and Auto-6, aliquots of isolated organoids
were transduced with DsRed lentivirus before being
implanted. Some of these aliquots were directly implanted,
while others were transferred into tissue culture to confirm
transduction efficiency. After 48 h in tissue culture,
transduced organoids expressed the red fluorescent marker
DsRed, confirming that the transduction was successful.
The cells in the organoids expressed the DsRed marker with
high intensity (Figs. 2c, d).
Intestinal Organoid Implantation and Explant Histology
Autotransplantation
In autotransplantation experiments, organoids were im-
planted into five different graft beds. In the subcutaneous
tissue, no evidence of intestinal mucosal growth was
observed in any of the 20 engraftment sites. The India ink
particles were observed in 22 of the implants marked with
the pigment, confirming that the subcutaneous tissue
analyzed contained the implantation sites.
In the omentum, both CFDA-labeled, DiI-labeled,
DsRed-lentivirus-labeled, and unlabeled control cells were
seeded. Groups of DiI- and CFDA-labeled cells were
identified in the graft beds by fluorescent microscopy.
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However, H&E analysis did not reveal any intestinal
mucosa (Figs. 3a–c). Examination of the 15 PGA biopoly-
mer tubes that were wrapped in omentum also did not
reveal any mucosa. The lumens of the tubes were oblit-
erated, and the scaffold material revealed abundant inflam-
matory cells and multinucleated giant cells (Fig. 3d).
Chemical debridement of the intestine with 60 min of
EDTA perfusion resulted in the dislodgement of approxi-
Figure 3 Organoid implantation
into omentum in autotransplanta-
tion. Fluorescent (×10, top) and
H&E (×4, bottom) images are
shown. Groups of CFDA (a) and
DiI (b) labeled cells were present
in the omentum. However, H&E
analysis showed absence of in-
testinal mucosa (c). PGA bio-
polymer tubes wrapped in
omentum revealed no intestinal
mucosa (d).
Figure 2 Fluorescent labeling
of ileal organoids. In autotrans-
plantation experiments, organo-
ids were successfully labeled
with a CFDA, b DiI, or trans-
duced with DsRed Lentivirus.
The organoids expressed DsRed
after 48 h in tissue culture
(c 0 h, d 48 h). All slides at ×20
magnification.
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mately 80% of the crypt mucosal cells from the basement
membrane. This amount of debridement had been shown to
produce an excellent graft bed in rodents.8,12 In dog Auto-
3, organoids had been implanted into graft beds that were
debrided in this way for 60 min. In sites where labeled
organoids had been seeded, some fluorescent cells were
observed. However, these fluorescent cells did not co-
localize to the DAPI-stained mucosa. This indicated that the
regeneration of mucosa in these debrided areas was not the
result of organoid engraftment but, rather, restitution from
the remaining quantities of native mucosa (Fig. 4a).
A total of ten (n=10) aliquots of organoids were seeded
into surgically debrided intestine (Auto-3, Auto-4, and
Auto-5). In all sites that were seeded with unlabeled ileal
organoids, there was no presence of ileal bile acid transport
protein staining by immunostaining with anti-ASBT anti-
body that cross-reacts with the dog transporter, which might
have indicated successful engraftment of ileal organoids.8,16
In sites where labeled organoids had been seeded (DiI,
DsRed), no engraftment of fluorescent cells was observed
4 weeks (Figs. 4b, c).
Allotransplantation
Animals had cyclosporine levels drawn on postoperative
days 5 and 14. The levels were within therapeutic range
(blood concentrations of 400–600 ng/ml), and no dosing
adjustments were necessary. After 4 weeks, H&E histology
revealed the presence of intestinal mucosa in 11 of 12
biopolymer tubes. Only the one biopolymer tube implanted
into Allo-4 failed to generate neomucosa. On gross
examination, the biopolymer tubes were completely envel-
oped with omentum with clearly visible, well-developed
blood vessels entering the bioscaffolds. The lumen of 11 of
the 12 biopolymer tubes, which proved on histology to
have intestinal neomucosa, grossly had large amounts of
mucus. On histology, the intestinal mucosa was indistin-
guishable from native dog intestine in structure and
composition, with fully formed crypts and villi (Fig. 5).
The enterocytes-and mucus-producing goblet cells were
present in the same location and proportions as in native
intestine. Furthermore, an extensive submucosal smooth
muscle layer was generated, which resembled the native
submucosal muscle layer.
Each 1-cm2 long PGA scaffold had a total available
surface area of 502.4 mm2 (internal surface area of each
tube=2πrh, where r=8 mm and h=10 mm). In the 11 of 12
biopolymer scaffolds in which neomucosa was observed, an
average of 303 mm2 per tube of neomucosa was generated.
The unseeded control biopolymer tubes demonstrated
fibrovascular ingrowth without any evidence of intestinal
mucosa.
Figure 4 Organoid implantation
into denuded intestine in auto-
transplantation. In chemically
debrided intestine, groups of
CFDA labeled cells were ob-
served; however, the signals did
not colocalize to the DAPI-
stained enterocytes (a; ×10). In
surgically debrided intestine, no
DiI (b) or DsRed (c) labeled cells
were identified in the graft beds
(×2.5).
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Discussion
This study represents the first report of the successful
generation of intestinal neomucosa using intestinal orga-
noid transplantation in a large animal model. There have
been several recent reports of generation of an intestinal
mucosal layer in dogs. In these studies, mucosal defects
were created in the small bowel and then bridged by
decellularized, porcine-derived small intestinal submucosa
or an acellular collagen sponge. These scaffolds then
became epithelialized from the adjacent native mucosa.17,18
However, this regenerated mucosa was not the result of
organoid transplantation; rather, it reflected the remarkable
wound healing capacity of the intestinal epithelium when a
mucosal injury or defect is created. The ability of intestinal
mucosal stem cells to divide and generate more mucosal
surface area in response to either injury or to loss of
mucosal surface area is well known.19–23 There has been
some thought that, perhaps, regeneration of intestinal
mucosa on biopolymer scaffolds in this way can generate
large amounts of mucosal surface area. However, there are
limits to the amount of mucosal regeneration that can take
place in response to mucosal injury or loss, and these repair
mechanisms cannot replace larger stretches of lost intestine.
Loss of intestine leads to mucosal hypertrophy and that
results in some functional compensation.24 However, loss
of 70–75% of the small intestine overwhelms this intestinal
adaptation response and leads to short bowel syndrome.4
With organoid transplantation, the amount of intestinal
mucosa that can be generated would, in principle, not be
Figure 5 Neomucosal growth
in allotransplantation. Neomu-
cosa generated on PGA bio-
polymer tubes (a) resembled
normal canine intestine in both
structure and composition. Fully
developed crypts and villi were
present with proportions of
enterocytes and goblet cells
(b–d) similar to normal
intestine (e).
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similarly limited. In the future, it may be possible to
amplify the intestinal stem cell clusters in vitro to generate
vast amounts of intestinal neomucosa.
In this present study, we optimize methods of intestinal
organoid isolation from canine juvenile ileum as well as
fetal intestine. With both isolation techniques, we were able
to obtain large amounts of viable intestinal organoids.
When fetal intestinal organoids were allotransplanted onto
PGA biopolymer tubes, a significant amount of intestinal
neomucosa was generated. This neomucosa resembled
native canine intestine in structure and composition. There
were the normal proportions of enterocytes and goblet cells,
and we observed the development of a well-formed
submucosal muscle layer similar to the native canine
intestine. In contrast, autotransplantation of juvenile orga-
noids into different graft beds (subcutaneous tissue,
omentum, biopolymer scaffolds, and debrided intestine)
failed to produce intestinal neomucosa in any of the
engraftment sites.
In the autotransplantation experiments, the recipient bed
preparation techniques were chosen based on our previous
experience with successful organoid transplantation in
rodent models. The omentum has been well established to
support the growth of intestinal neomucosa after organoid
transplantation in rodents.11,13,25–27. Furthermore, we have
previously reported successful intestinal resurfacing in
rodents.8 In these autotransplantation experiments, a total
of 79 seeding experiments were performed with intestinal
organoids that were either unlabeled or labeled with
different vital stains. In organoids labeled with DiI or
CFDA, we observed strong staining of the organoid clusters
at the time of seeding. After 4 weeks time, many recipient
graft beds still contained fluorescently labeled cells.
However, the pattern of fluorescence did not suggest the
presence of intestinal mucosa, and subsequent H&E
staining confirmed its absence. It is possible that these
fluorescently labeled cells represent the persistence of a
mesenchymal component of the organoids. A weakness of
our studies may be that no further tests were performed to
investigate the ratio of labeled mesenchymal and labeled
mucosal cells. Thus, we cannot exclude the possibility that
rare non-labeled mucosal cells engrafted into a recipient
bed but eluded detection. However, in our experiments, the
stained cells were mainly used as a guide to help us focus
where we would expect to find neomucosa in the recipient
segment. The ultimate determination of the presence of
neomucosa was made by analysis of H&E-stained slides. In
these slides, we specifically looked for mucosal cell
formations in the graft beds. In all of the experiments
where the organoids were labeled with vital stains, an
aliquot of unlabeled organoids was implanted. Since neo-
mucosa was not found in any of these control engraftment
sites, it is unlikely that the labeling of organoids itself
affected the long-term viability or the implantation of the
organoids.
In contrast to the autotransplantation experiments where
juvenile organoids were used, the use of fetal intestinal
organoids transplanted onto PGA biopolymer tubes gener-
ated neomucosa in almost all samples. Only the one PGA
tube implanted into Allo-4 failed to generate neomucosa.
This is not easily explained; it is unlikely that this lack of
engraftment was due to rejection, since there was no
histologic evidence for this. In this experimental series,
we chose to transplant the organoids onto PGA tubes
wrapped in omentum, since this had developed into a gold-
standard for testing of neonatal organoids in rodents in our
laboratory during the time period the dog studies were
conducted. We avoided cell labeling in this case as a
possible confounding factor, since any mucosa grown in the
confined luminal space of the PGA tube would evidently be
derived from the transplanted organoids.
Why autotransplantation of juvenile organoids failed to
generate neomucosa whereas allotransplantation of fetal
organoids succeeded is not easily explained. However, this
result is comparable to previous experience in rodents5,7
(Stelzner, unpublished data). As noted above, generation of
small intestinal neomucosa has been reported in different
animal species previously when neonatal donors were used.
In contrast, successful use of adult organoid donors has
never been reported in the literature to our knowledge. It is
therefore conceivable that juvenile or adult small intestinal
canine organoids do not give rise to a neomucosa, e.g.,
because they are in some way too differentiated. However,
this hypothesis would have to be addressed in future
studies.
In both groups, large amounts of organoids were
harvested, and equal amounts were seeded onto similar
graft beds. It is conceivable that the fetal intestinal organo-
ids are more primitive and more vigorous than the juvenile
intestinal organoids. Evidence to support this assumption
for enterocytes is sparse, but Guillot et al. has recently
shown that fetal mesenchymal stem cells express more
pluripotency markers, have longer telomeres, and are more
readily expandable and senesce later in culture than their
adult counterparts.28,29. The present pilot study has addi-
tional limitations since the autotransplantation group is in
other aspects not comparable to the allotransplantation
group. For example, it is possible that the immunosuppres-
sive medications enhanced organoid implantation or acted
as a growth stimulus for the mucosa. Investigation of such
drug actions would have exceeded the scope of this study
of and would need to be further elucidated.
We have demonstrated in this study that generating
intestinal neomucosa with organoid transplantation is
feasible in large animals. As with any potential clinical
therapy, demonstration of a “proof of principle” is generally
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accepted as an important milestone before considering
human studies. Some obstacles still remain before intestinal
organoid transplantation could be used for therapy in
human applications such as the treatment of short bowel
syndrome or malabsorption syndromes. Currently, no
methods exist to successfully harvest and transplant adult
intestinal epithelial stem cells, which would appear more
widely applicable than transplantation of fetal cells.5 The
lack of availability and banking of neonatal or fetal cells
from human donors also currently limits the feasibility of
this approach for clinical applications. This is not different
from several other areas of stem cell transplantation.
Furthermore, intestinal organoid transplantation only gen-
erates the intestinal mucosal layer. Recently, Nakase et
al.30,31 reported that transplantation of smooth muscle cells
onto collagen sponge scaffolds results in generation of both
an intestinal smooth muscle layer as well as enteroendo-
crine cells and nerve tissue in the tissue-engineered small
intestinal segment. However, generation of a functional,
peristaltic neuromuscular unit has still not been reported.
Finally, a very large number of transplantable cells would
need to be available before attempts at producing
bioengineered human intestinal mucosa can be made. In
our previous rat model, we were able to produce enough
neomucosa using organoid transplantation to cure a
clinical malabsorption syndrome.10 This is very encour-
aging; however, good methods to amplify the stem cell
mass to bioengineeer adequately large neomucosal seg-
ments in humans are not yet available. A concerted effort
to make progress in these areas is necessary for intestinal
organoid transplantation to become part of our clinical
armamentarium.
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